The Efficacy and Safety of Ferriprox for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anaemias

Trial Profile

The Efficacy and Safety of Ferriprox for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anaemias

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Deferiprone (Primary) ; Deferoxamine
  • Indications Iron overload
  • Focus Therapeutic Use
  • Acronyms FIRST
  • Sponsors ApoPharma
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 10 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2019.
    • 10 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top